Samuel M. Rubinstein

Samuel M. Rubinstein, MD is an Associate Professor of Medicine in the Division of Hematology at the University of North Carolina Chapel Hill School of Medicine and an associate member of the Lineberger Comprehensive Cancer Center.

Education:

• Undergraduate: Northwestern University
• Medical School: University of Illinois at Chicago
• Residency: Vanderbilt University Medical Center
• Fellowship: Vanderbilt University Medical Center

Dr. Rubinstein specializes in plasma cell disorders including multiple myeloma, light-chain (AL) amyloidosis, and monoclonal gammopathies. His research focuses on clinical trials designed to improve standard of care for patients with plasma cell dyscrasias. With a strong background in clinical informatics, he has developed multiple prognostic scoring tools for managing patients with these disorders. During the COVID-19 pandemic, he expanded his research to examine the impacts of COVID-19 on cancer patients, serving as site PI of the COVID-19 and Cancer Consortium (CCC19) at UNC. His work with CCC-19 has produced numerous studies addressing clinically relevant questions about epidemiology and outcomes of cancer patients with COVID-19.

Dr. Rubinstein's research demonstrates a strong integration of clinical hematology with informatics approaches, particularly in developing tools for prognostic assessment in plasma cell disorders. His more recent work bridges hematology/oncology with infectious disease challenges presented by the pandemic.

As an active clinician-researcher at UNC, Dr. Rubinstein contributes to both patient care in the hematology division and research initiatives through the Lineberger Comprehensive Cancer Center. His work with CCC-19 represents significant collaboration across institutions to address urgent clinical questions during the pandemic.

Dr. Rubinstein maintains his clinical practice while leading research initiatives in plasma cell disorders and cancer-pandemic interactions. His laboratory and clinical work focuses on developing better risk stratification tools and therapeutic approaches for patients with plasma cell dyscrasias.